With a compound annual growth rate of only 2.6% over the past five years, China's top 100 pharmaceutical companies are entering an adjustment period. How will the industry break through under internal and external pressures?

According to the data from China Meheco Group, in 2023, multiple operation indicators of the pharmaceutical industry's leading companies have declined. The compound annual growth rate of the top 100 pharmaceutical companies in the country in the past five years is only 2.6%, and the industry as a whole has entered the adjustment phase from the initial high-speed growth. Behind the weak growth, the health industry is also undergoing transformation: overseas licensing trades for innovative drugs have reached a new high, and leading companies are accelerating outward expansion...

cls.cn20:54 ET

Weak revenue from innovative drugs has dragged down performance. Simcere Pharma has introduced a new drug for lung cancer to expand its product portfolio.

①Simcere Pharma introduced an innovative drug for the treatment of non-small cell lung cancer with an upfront payment of $20 million. Currently, the company has a total of 7 commercialized innovative drug products, covering areas such as oncology, immunology, and the nervous system. ②In the first half of the year, the performance of innovative drug sales was weak, leading to a decline in Simcere Pharma's overall revenue and net income, as well as a synchronous decrease in R&D investment in innovative drugs.

cls.cnSep 3 04:37 ET

Is the chain of pharmacies entering a "mini ice age"? H1 growth rate "downgrades", the industry's high-growth stores may reach turning point.

① The growth rate of sales revenue of all categories in retail pharmacies has slowed down, and the competition in stock continues to intensify. In the first half of this year, it was difficult for major chain pharmacies to increase revenue and profit. ② In the future, the focus of pharmacy competition will shift to commodity extension and services. According to the prediction of Zhongkang Industry Research Institute, the growth rate of pharmaceuticals in all end terminals in 2024 is expected to decrease to 4.9%, a decrease from 2023.

cls.cnSep 2 05:25 ET

Will you be eliminated if you don't go overseas? In the first half of the year, the proportion of innovative drug outbound business development accounted for about 80% | Industry Dynamics.

①At the 2024 New Investment Conference hosted by Frost Sullivan, the issue of going global was favored by participants. ②There is a new trend in the export of innovative drugs in China, for example, the number of export BDs exceeded License-in for the first time in 2023. ③Some participating experts put forward rational opinions and called for internal strength, not just enthusiasm.

cls.cnAug 31 03:06 ET

HUTCHMED Pulls Regulatory Submission for Takeda-partnered Cancer Drug in China

Seeking AlphaAug 30 07:43 ET

The market is booming as Johnson, an innovative drug company, sees a 13% increase in performance | Jiann zhiyan Research

The market should not lose confidence in China's innovative drugs.

wallstreetcnAug 28 20:36 ET